12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

APF530 regulatory update

A.P. Pharma resubmitted an NDA to FDA for APF530 to prevent chemotherapy-induced nausea and vomiting (CINV). The company said the application includes responses to FDA's 2010 complete...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >